Expert Interview
A Second Look: Discussing the potential use of CT-155, a prescription digital therapeutic (PDT) designed to treat the negative symptoms of schizophrenia from Boehringer Ingelheim and Click Therapeutics.
Ticker(s): BOEHRINGER INGELHEIM, Click TherapeuticsInstitution: Jefferson University Hospitals
- Double-boardcertified in Psychiatry and Psychosomatic Medicine
- Manages patients with avariety of mental illness, including depression, anxiety, schizophrenia, dementia, bipolardisorder, and ADHD
- Currently manages 60 patients with bipolar disorder, 100 with schizophrenia and 100 with Alzheimer's agitation.
- Has prescribed Caplyta to his patients since approval, and is very familiar with KarXt and the unmet needs in the treatment of schizophrenia
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
